SCARB1 (SR-BI) Drug Discovery Landscape & Assay Solutions
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Atherosclerosis, NASH, and Infectious Disease Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCARB1-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCARB1 ECD-Fc Fusion Protein High purity (>95%), HEK293 expressed (native glycosylation), Endotoxin <1EU/μg. Sequence Verified. |
View SCARB1 Products |
| Gene Delivery | SCARB1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines (HepG2, Huh7). Preserves native topology for internalization and lipid uptake assays. |
View SCARB1 Products |
| Benchmark Ab | Anti-SCARB1 Neutralizing Antibody (Reference Sequence) Recombinant monoclonal for assay standardization and positive control. |
View SCARB1 Products |
| Validator | SCARB1 siRNA Set (3 pre-designed) For functional knockdown verification in fatty acid uptake assays. |
View SCARB1 Products |
| Related Target | CD36 (SCARB3) Compensatory lipid uptake receptor; essential for combination therapy and selectivity screening. |
View CD36 Products |
| Related Target | SCARB2 (LIMP-2) Lysosomal receptor; critical off-target liability for cross-reactivity panels. |
View SCARB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species liver metabolism evaluation | Human/Mouse/Cyno SCARB1 ortholog proteins available with >95% purity; sequence identity verified |
| Subfamily selectivity (SCARB2/CD36) | SCARB2 and CD36 homolog proteins strictly verified by mass spec for counter-screening |
| Functional lipid uptake validation | Lentivirus-delivered full-length SCARB1 maintains native conformation for BODIPY-cholesterol uptake assays |
| Assay specificity controls | Validated siRNA and benchmark antibodies included for orthogonal verification |
Live SCARB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCARB1 (SR-BI) therapeutics is intensifying, with major players shifting focus from broad lipid modulation to tissue-specific pathway intervention. As first-generation small molecules face challenges with hepatoselectivity, the next wave of R&D is targeting biologics capable of distinguishing between protective hepatic HDL uptake and pathogenic macrophage lipid loading. Emerging applications in infectious disease (malaria sporozoite inhibition) and cancer immunometabolism (tumor-associated macrophage reprogramming) are expanding the indication landscape beyond cardiovascular disease.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking Antibodies | Infectious Disease Biotechs, Academic Consortia | Malaria Prophylaxis, HCV Entry Inhibition | Ligand Competition Assay (Need high-purity ECD-Fc with native glycosylation for CSP/E2 binding) |
| Small Molecule Inhibitors | Cardiovascular-focused Pharma | NASH, Atherosclerosis | Selective Lipid Uptake Assay (Need Lentivirus-based stable cell lines for functional validation) |
| ADC |